-
Mashup Score: 4U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug - 2 year(s) ago
The U.S. Food and Drug Administration said on Wednesday GlaxoSmithKline and Vir Biotech’s COVID-19 antibody treatment should not be used in places with circulation of variants that are not susceptible to the drug.
Source: ReutersCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 91Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant - 2 year(s) ago
Conflicting reports are raising questions about whether the Covid-19 monoclonal antibody sotrovimab — the one such treatment that has continued to work against the Omicron variant — maintains its power against a sister form of the virus, BA.2.
Source: STATCategories: Expert Picks, Latest HeadlinesTweet-
Conflicting reports about whether #Covid19 monoclonal antibody #sotrovimab (the one such treatment that has continued to work against the Omicron variant) maintains its power against a sister form of the virus, #BA2 https://t.co/pmfqzrwH8D via @statnews
-
After the immunity-escaping Omicron variant emerged, sotrovimab was the last monoclonal antibody therapy left standing. Has the Omicron's subvariant BA.2 rendered it ineffective as well? As @DrewQJoseph writes, the answer depends on who you ask. https://t.co/EVDK4Nf9Rk
-
-
Mashup Score: 7
The FDA curbed the use of two out of three monoclonal antibody treatments. Studies show they’re highly unlikely to work against the omicron variant, which is overwhelming hospitals.
Source: NPR.orgCategories: Infectious Disease, Latest HeadlinesTweet-
With #Sotrovimab in scarcity, our program has adopted IV #remdesivir as another option for early treatment of high-risk patients with mild to moderate covid19 https://t.co/eCL7Ewp2N0
-
-
Mashup Score: 0'Mild COVID' isn't always mild: Tips for recovering at home - 2 year(s) ago
“The majority of the treatment of mild to moderate COVID is aimed at relieving symptoms,” an expert said of those treating themselves at home.
Source: ABC NewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Mild COVID' isn't always mild: Tips for recovering at home https://t.co/zs6JhrG5sv via @ABC Also there are treatments for high risk people via @NIH https://t.co/CxzS6riV7k - #Paxlovid within 5d of sxs - #Sotrovimab within 10d - #Remdesivir within 7d - #Molnupiravir within 5d
-
-
Mashup Score: 3A living WHO guideline on drugs for covid-19 - 2 year(s) ago
Updates This is the eighth version (seventh update) of a living guideline. It replaces earlier versions (4 September 2020, 20 November 2020, 17 December 2020, 31 March 2021, 6 July 2021, 23 September 2021, and 6 December 2021). The previous versions can be found as data supplements. New recommendations will be published as updates to this guideline. Clinical question What is the role of drugs in…
Source: The BMJCategories: Infectious Disease, Latest HeadlinesTweet-
New #COVID19 #Therapeutics guidance out today from @WHO clinical team in @bmj_latest 1. Conditional recommendation for #Sotrovimab in non-severe disease 2. Strong recommendation for #Baricitinb in severe and critical disease cc @diazjv @mvankerkhove https://t.co/aFfHCcr316 https://t.co/BEnSgx0WcP
-
-
Mashup Score: 6Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19 - Ontario COVID-19 Science Advisory Table - 2 year(s) ago
Citation: Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group. Clinical practice guideline summary: recommended drugs and biologics in adult patients with COVID-19. Ontario COVID-19 Science Advisory Table. 2022; Version 7.0. https://doi.org/10.47326/ocsat.cpg.2022.7.0 Author Affiliations: The affiliations of the members of the Ontario COVID-19 Science Advisory…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Updated guidance from our CPG guideline panel @COVIDSciOntario - evidence and ethically based, multistakeholder, reflective of current supply challenges. LOTS of new stuff for mildly ill & outpatients: #fluvoxamine #budesonide #sotrovimab #remdesivir https://t.co/uRNUgo19gK
-
-
Mashup Score: 0Statement on Therapies for High-Risk, Nonhospitalized Patients | COVID-19 Treatment Guidelines - 2 year(s) ago
Review this statement about using the currently available therapies to treat COVID-19 in certain nonhospitalized patients.
Source: COVID-19 Treatment GuidelinesCategories: Critical Care, Latest HeadlinesTweet-
The NIH has released Rx guidelines for folks w/ COVID and high risk of severe disease. In order of preference they recommend one of the following: - #Paxlovid if within 5d of sxs - #Sotrovimab within 10d - #Remdesivir within 7d - #Molnupiravir within 5d https://t.co/cQY3Czr5jh
-
-
Mashup Score: 4The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic - 2 year(s) ago
The SARS-CoV-2 Omicron variant is rapidy spreading worldwide and a public health concern. Experiments show that this variant resistant against several therapeutic antibodies for COVID-19 and efficiently evades antibodies induced upon infection or double BNT162b2 vaccination, however not triple BNT162b2 or ChAdOx1/BNT162b2 vaccination.
Source: CellCategories: Hematologists1, Latest HeadlinesTweet-
The #Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the #COVID19 pandemic: Cell. Some protection by booster vaccination (3x BNT). Therapeutic antibodies with reduced efficacy, except #Sotrovimab. https://t.co/hfaLulNZtN https://t.co/zPt6yHBNJV
-
-
Mashup Score: 2GSK-Vir antibody COVID-19 therapy to be tested in large UK study - 2 year(s) ago
GSK and Vir Biotechnology’s antibody-based COVID-19 drug is being studied as a possible treatment for hospitalised patients in a large British study looking into coronavirus therapies, researchers said on Thursday.
Source: ReutersCategories: Infectious Disease, Latest HeadlinesTweet-
This is great! With it appearing most mAbs don’t neutralize #Omicron and lab studies indicating #Sotrovimab may work, excited to see the #UK #RECOVERY trial is planning on testing this mAb as part of its trial starting as early as next week https://t.co/pFbRXE9dk8
-
-
Mashup Score: 1Sotrovimab Reduces Risk of Disease Progression in High-Risk Adults with Symptomatic COVID-19 - 3 year(s) ago
The monoclonal antibody sotrovimab reduced the risk of hospitalization or death by 85% in high-risk patients with mild-to-moderate COVID-19.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet-
The monoclonal antibody #sotrovimab reduces the risk of hospitalization or death by 85% in high-risk adults with symptomatic #COVID19. https://t.co/kWaxZ2h0zH
-
In things closer to home, @US_FDA limits use of GlaxoSmithKline-Vir #sotrovimab #COVID19 monoclonal antibody against Omicron BA.2 variant. whack-a-mole continues. #IDTWitter https://t.co/xkE1tNIhFy